Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc.

The company's equity performance has been challenging throughout the year. Even after Wednesday's substantial advance, the stock remains down 37% year-to-date. Moderna's most recent quarterly report ...

The company's push deeper into a hot new technology, plus good news from a top collaborator, put the shine on its equity.

Pharmaceutical stocks gained Wednesday afternoon amid anticipation Pfizer's deal with the Trump administration could lead to more with other firms.

Nike trades higher after the sneaker and athletic apparel company’s quarterly earnings beat Wall Street estimates.

Moderna stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector.

CureVac's (CVAC) mRNA innovations, strong patent portfolio, and investment potential. Learn the risks and rewards of this ...

A pair of pharmaceutical giants spearheaded gains for other stocks in the industry on Tuesday, Sept. 30, 2025, while a new OpenAI partnership weighed on payments providers.

Regeneron's revenue in the second quarter increased by 4% year over year to $3.68 billion. That's not phenomenal top-line ...

Discover 3 top biotech stocks under $10 with lucrative options for covered call strategies. Click for these under-the-radar ...

In the closing of the recent trading day, Moderna (MRNA) stood at $24.61, denoting a -4.91% move from the preceding trading day.